<DOC>
	<DOCNO>NCT00109265</DOCNO>
	<brief_summary>This Phase II , multicenter trial single-agent treatment OSI 774 patient histologically confirm , incurable , locally advanced metastatic breast cancer . Patients must measurable disease .</brief_summary>
	<brief_title>A Study Evaluate Erlotinib Patients With Advanced Metastatic Breast Cancer During Following Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed informed consent Women &gt; =18 year age Histologically document , incurable , locally advanced metastatic breast cancer Disease progression therapy anthracycline , taxane , capecitabine ( Cohort 1 ) , disease progression therapy least one chemotherapy regimen locally advance metastatic disease ( Cohort 2 ) Measurable disease &gt; =2 cm ( &gt; =1 cm spiral CT scan ) . Disease previously irradiate site consider measurable clear disease progression follow radiation therapy . HER2 negative , HER2 unknown , HER2 positive disease progression follow Herceptin ( R ) ( trastuzumab ) therapy ECOG performance status 0 2 Life expectancy &gt; =3 month Use effective mean contraception woman childbearing potential Ability comply study followup procedures Pleural effusion blastic bone lesion manifestation current metastatic breast cancer Other primary malignancy within 5 year except adequately treat carcinoma situ cervix basal squamous cell skin cancer Symptomatic untreated brain metastasis Radiotherapy , immunotherapy , hormonal therapy , chemotherapy within 21 day prior Day 0 ( 6 week nitrosoureas mitomycin ) ; prior therapy agent design target either EGFR EGFRspecific tyrosine kinase activity INR &gt; 4.0 patient receive warfarin Cumulative anthracycline anthracenedione exposure follow : doxorubicin &gt; 450 mg/m , liposomal doxorubicin &gt; 550 mg/m , epirubicin &gt; 700 mg/m , mitoxantrone &gt; 140 mg/m Cardiac ejection fraction ( MUGA echocardiogram ) less local institution lower limit normal Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 0 , serious cardiac arrhythmia require medication Major surgery , biopsy parenchymal organ , significant traumatic injury occur within 21 day prior Day 0 History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Abnormalities cornea base history ( e.g. , dry eye syndrome , Sjogren 's syndrome ) , congenital abnormality ( e.g. , Fuch 's dystrophy ) , abnormal slitlamp examination use vital dye ( e.g. , fluorescein , BengalRose ) , and/or abnormal corneal sensitivity test ( Schirmer test similar tear production test ) Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease Pregnancy lactation Any follow abnormal baseline hematologic value : *Granulocyte count &lt; =1500/uL ; *Platelet count &lt; 100,000/uL ; *Hemoglobin &lt; 9 gm/dL ( transfusion permit ) Any follow abnormal baseline liver function test : *Serum bilirubin &gt; =1.5x upper limit normal ( ULN ) ; *Serum ALT AST &gt; =2.5x ULN ( &gt; 5x ULN due liver metastasis ) ; *Alkaline phosphatase &gt; =2.5x ULN ( &gt; 4x ULN due liver bone metastasis ) Other baseline laboratory value : *Serum creatinine &gt; =1.5x ULN creatinine clearance &lt; =60 mL/min ; *Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) ; *Serum albumin &lt; =3.0 g/dL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>